在炎症性肠病中实施需要输液和注射的生物药物的电子流表
Jessica Fann1, Miranda Murray1, Josh DeClercq1
1Vanderbilt Health, Vanderbilt Specialty Pharmacy, Nashville, TN.
Journal of the American Pharmacists Association : JAPhA
|March 9, 2026
概括
一个新的电子健康记录流表简化了炎症性肠病 (IBD) 患者的生物药物管理. 这种工具改善了工作流程,数据可见性和输注到皮下剂量过渡的报告.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 医疗信息学 医疗信息学
背景情况:
- 针对炎症性肠病 (IBD) 的生物药物通常涉及复杂的剂量,从输液开始,然后过渡到皮下 (SC) 维护.
- 这些转变是时间敏感的,需要仔细协调保险批准和药物获取.
研究的目的:
- 提高工作流程效率和数据可见性,用于管理在SC剂量之前开始生物输注的患者.
- 实施电子健康记录 (EHR) 流表,以改善患者旅程的跟踪和报告.
主要方法:
- 在一个学术卫生系统的IBD门诊中开发并实施了一个EHR流表.
- 流表集成了输液和专业药剂师的工作流程文档,捕获关键的患者旅程数据并提供警报.
- 进行了实施后的调查和流表数据的描述性分析.
主要成果:
- 药剂师调查显示,他们对流程表的满意度很高 (9.2/10),他们强烈同意增加可见性和简化工作流程.
- 流表允许捕获以前无法获得的数据,包括从转诊到第一次输液的时间 (中位数为22天).
- 输液中心 (66%) 和专业药房 (52%) 的捕获率在实施后报告.
结论:
- 实施EHR流程表显著简化了管理生物输液的IBD患者的工作流程.
- 流表提高了数据可见性,并改善了关键治疗里程碑的数据捕获.
- 这项创新支持在IBD护理中更好地协调和管理复杂的生物剂量方案.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
883
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
883
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
629
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
629
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
688
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
688
Flow Sheet
3.0K
Flowsheets are valuable tools in nursing documentation. They enable healthcare professionals to efficiently record and monitor various patient assessments and measurements in a consolidated format.
Here's a closer look at the examples of flowsheets commonly used by nurses:
Graphic Sheet Documentation:
Here's a closer look at the examples of flowsheets commonly used by nurses:
Graphic Sheet Documentation:
3.0K
Methods of Documentation VII: EMR
1.5K
Electronic Medical Records (EMRs) primarily center around electronically documenting patients' health information within a single healthcare organization or practice. They contain essential clinical data related to a patient's medical history, diagnoses, medications, treatment plans, lab results, and other pertinent information relevant to the specific encounter or episode of care. EMRs are designed to streamline documentation and workflow processes within individual healthcare...
1.5K
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices
84
Parenteral drug delivery systems play a crucial role in modern therapeutics by enabling the direct administration of drugs into the systemic circulation, bypassing the gastrointestinal tract. These systems are particularly valuable for poorly absorbed oral medications that are unstable in the digestive environment or require rapid onset or sustained therapeutic levels. Delivery is achieved through intravenous, intramuscular, or subcutaneous routes, each selected based on the drug's properties...
84


